These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32980465)

  • 1. The outstanding antitumor capacity of CD4
    Li T; Wu B; Yang T; Zhang L; Jin K
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188439. PubMed ID: 32980465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Antitumor CD4
    Ben Khelil M; Godet Y; Abdeljaoued S; Borg C; Adotévi O; Loyon R
    Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].
    Nishimura T; Kuge S; Watanabe K; Lee U; Yahata T; Habu S
    Hum Cell; 1994 Sep; 7(3):131-7. PubMed ID: 7873496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering CD4
    Kirkpatrick C; Lu YW
    Mol Carcinog; 2024 Jul; 63(7):1209-1220. PubMed ID: 38725218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Wang B; Hu S; Fu X; Li L
    Adv Biol (Weinh); 2023 Apr; 7(4):e2200169. PubMed ID: 36193961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4
    Magen A; Nie J; Ciucci T; Tamoutounour S; Zhao Y; Mehta M; Tran B; McGavern DB; Hannenhalli S; Bosselut R
    Cell Rep; 2019 Dec; 29(10):3019-3032.e6. PubMed ID: 31801070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
    Song L; Yang MC; Knoff J; Wu TC; Hung CF
    PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Reprogramming of CD4
    Renaude E; Kroemer M; Borg C; Peixoto P; Hervouet E; Loyon R; Adotévi O
    Front Immunol; 2021; 12():669992. PubMed ID: 34262562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
    Mylvaganam G; Yanez AG; Maus M; Walker BD
    Front Immunol; 2019; 10():2109. PubMed ID: 31552045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
    Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
    Front Immunol; 2018; 9():1301. PubMed ID: 29930558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.